-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
BiondVax Pharmaceuticals (NASDAQ:BVXV) Versus Bio-Techne (NASDAQ:TECH) Head-To-Head Contrast
BiondVax Pharmaceuticals (NASDAQ:BVXV) Versus Bio-Techne (NASDAQ:TECH) Head-To-Head Contrast
Bio-Techne (NASDAQ:TECH – Get Rating) and BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
Institutional & Insider Ownership
23.9% of Bio-Techne shares are held by institutional investors. 4.5% of Bio-Techne shares are held by insiders. Comparatively, 6.0% of BiondVax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Get Bio-Techne alerts:Valuation and Earnings
This table compares Bio-Techne and BiondVax Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bio-Techne | $1.12 billion | 11.05 | $272.05 million | $1.78 | 44.20 |
BiondVax Pharmaceuticals | N/A | N/A | -$12.85 million | ($4.04) | -0.64 |
Volatility and Risk
Bio-Techne has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, BiondVax Pharmaceuticals has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Bio-Techne and BiondVax Pharmaceuticals, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bio-Techne | 0 | 2 | 5 | 0 | 2.71 |
BiondVax Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Bio-Techne currently has a consensus target price of $107.86, indicating a potential upside of 37.09%. Given Bio-Techne's higher probable upside, research analysts clearly believe Bio-Techne is more favorable than BiondVax Pharmaceuticals.
Profitability
This table compares Bio-Techne and BiondVax Pharmaceuticals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Bio-Techne | 26.13% | 16.37% | 12.16% |
BiondVax Pharmaceuticals | N/A | -230.46% | -35.35% |
Summary
Bio-Techne beats BiondVax Pharmaceuticals on 10 of the 12 factors compared between the two stocks.
About Bio-Techne
(Get Rating)
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. T
About BiondVax Pharmaceuticals
(Get Rating)
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
Bio-Techne (NASDAQ:TECH – Get Rating) and BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
生物科技(纳斯达克:TECH-GET评级)和生物威士制药(纳斯达克:BVXV-GET评级)都是医药公司,但哪只股票更优?我们将根据这两家公司的风险、估值、机构所有权、收益、盈利能力、股息和分析师的建议来比较它们的实力。
Institutional & Insider Ownership
机构与内部人持股
23.9% of Bio-Techne shares are held by institutional investors. 4.5% of Bio-Techne shares are held by insiders. Comparatively, 6.0% of BiondVax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Bio-Techne公司23.9%的股份由机构投资者持有。Bio-Techne 4.5%的股份由内部人士持有。相比之下,BiondVax PharmPharmticals 6.0%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一家公司的长期表现将好于大盘。
Valuation and Earnings
估值和收益
This table compares Bio-Techne and BiondVax Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
该表格比较了Bio-Techne和BiondVax制药公司的营收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bio-Techne | $1.12 billion | 11.05 | $272.05 million | $1.78 | 44.20 |
BiondVax Pharmaceuticals | N/A | N/A | -$12.85 million | ($4.04) | -0.64 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
生物技术 | 11.2亿美元 | 11.05 | 2.7205亿美元 | $1.78 | 44.20 |
BiondVax制药 | 不适用 | 不适用 | -1,285万元 | ($4.04) | -0.64 |
Volatility and Risk
波动性和风险
Bio-Techne has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, BiondVax Pharmaceuticals has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500.
BioTechne的贝塔系数为1.25,这表明其股价的波动性比标准普尔500指数高出25%。相比之下,BiondVax PharmPharmticals的贝塔系数为2.65,这表明其股价的波动性比标准普尔500指数高165%。
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and price targets for Bio-Techne and BiondVax Pharmaceuticals, as reported by MarketBeat.com.
据MarketBeat.com报道,这是Bio-Techne和BiondVax制药公司最近的评级和目标价细分。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bio-Techne | 0 | 2 | 5 | 0 | 2.71 |
BiondVax Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
生物技术 | 0 | 2 | 5 | 0 | 2.71 |
BiondVax制药 | 0 | 0 | 0 | 0 | 不适用 |
Bio-Techne currently has a consensus target price of $107.86, indicating a potential upside of 37.09%. Given Bio-Techne's higher probable upside, research analysts clearly believe Bio-Techne is more favorable than BiondVax Pharmaceuticals.
BioTechne目前的共识目标价为107.86美元,表明潜在上涨37.09%。鉴于Bio-Techne更有可能上行,研究分析师显然认为Bio-Techne比BiondVax PharmPharmticals更有利。
Profitability
盈利能力
This table compares Bio-Techne and BiondVax Pharmaceuticals' net margins, return on equity and return on assets.
此表比较了Bio-Techne和BiondVax制药公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Bio-Techne | 26.13% | 16.37% | 12.16% |
BiondVax Pharmaceuticals | N/A | -230.46% | -35.35% |
净利润率 | 股本回报率 | 资产回报率 | |
生物技术 | 26.13% | 16.37% | 12.16% |
BiondVax制药 | 不适用 | -230.46% | -35.35% |
Summary
摘要
Bio-Techne beats BiondVax Pharmaceuticals on 10 of the 12 factors compared between the two stocks.
在两只股票的12项指标中,BioTechne有10项超过了BiondVax PharmPharmticals。
About Bio-Techne
关于生物技术公司
(Get Rating)
(获取评级)
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. T
生物技术公司致力于为研究和临床诊断市场开发、制造和销售生物技术试剂和仪器。它通过以下部门运作:蛋白质科学和诊断以及基因组学。蛋白质科学部门开发和制造纯化的蛋白质和试剂溶液,最主要的是细胞因子和生长因子、抗体、免疫分析、生物活性小分子化合物、组织培养试剂和T细胞激活技术。这一领域还包括蛋白质分析解决方案,为研究人员提供高效和简化的自动化蛋白质印迹和多路酶联免疫吸附试验工作流程选项。诊断和基因组学部门开发和制造诊断产品,包括用于OEM和临床客户的FDA规定的对照、校准器、血气和临床化学对照和其他试剂,以及临床分子诊断肿瘤学分析组合,包括用于前列腺癌诊断的ExoDx前列腺癌(IntelliScore)测试(EPI)。这一部门还制造和销售先进的组织原位杂交分析(ISH),用于研究和临床使用。T
About BiondVax Pharmaceuticals
关于BiondVax制药公司
(Get Rating)
(获取评级)
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
BiondVax制药有限公司是一家临床阶段的生物制药公司,致力于传染病免疫调节疗法的开发和商业化。它的重点是候选流感疫苗,该疫苗旨在提供针对季节性和大流行性流感的多毒株和多季节保护。该公司由Ronald Babecoff和Rami Epstein于2003年7月21日创立,总部设在以色列耶路撒冷。
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
获得《生物技术日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对Bio-Techne及相关公司评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧